- Home
- MCRI vs TARS Comparison
MCRI vs TARS Comparison
Compare MCRI & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRI
- TARS
- Stock Information
- Founded
- MCRI 1972
- TARS 2016
- Country
- MCRI United States
- TARS United States
- Employees
- MCRI N/A
- TARS 323
- Industry
- MCRI Hotels/Resorts
- TARS Medicinal Chemicals and Botanical Products
- Sector
- MCRI Consumer Discretionary
- TARS Health Care
- Exchange
- MCRI Nasdaq
- TARS Nasdaq
- Market Cap
- MCRI 1.6B
- TARS 1.7B
- IPO Year
- MCRI 1993
- TARS 2020
- Fundamental
- Price
- MCRI $100.13
- TARS $42.04
- Analyst Decision
- MCRI Hold
- TARS Strong Buy
- Analyst Count
- MCRI 5
- TARS 7
- Target Price
- MCRI $96.20
- TARS $67.14
- AVG Volume (30 Days)
- MCRI 185.5K
- TARS 574.0K
- Earning Date
- MCRI 07-16-2025
- TARS 08-11-2025
- Dividend Yield
- MCRI 1.18%
- TARS N/A
- EPS Growth
- MCRI N/A
- TARS N/A
- EPS
- MCRI 4.22
- TARS N/A
- Revenue
- MCRI $534,693,999.00
- TARS $233,674,000.00
- Revenue This Year
- MCRI $6.37
- TARS $122.94
- Revenue Next Year
- MCRI $4.55
- TARS $44.14
- P/E Ratio
- MCRI $24.06
- TARS N/A
- Revenue Growth
- MCRI 4.65
- TARS 449.03
- 52 Week Low
- MCRI $69.99
- TARS $20.08
- 52 Week High
- MCRI $113.88
- TARS $57.28
- Technical
- Relative Strength Index (RSI)
- MCRI 60.28
- TARS 51.55
- Support Level
- MCRI $100.13
- TARS $38.51
- Resistance Level
- MCRI $102.80
- TARS $42.11
- Average True Range (ATR)
- MCRI 2.86
- TARS 1.73
- MACD
- MCRI -0.63
- TARS 0.03
- Stochastic Oscillator
- MCRI 6.47
- TARS 44.69
About MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.